Alto Neuroscience, Inc. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Alto Neuroscience, Inc. (ANRO) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 7.36 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-12
- Alto Neuroscience, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 7.25M shares, a 23.37% increase year-over-year.
- Alto Neuroscience, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-03-31 was 5.88M shares, a 27.83% increase year-over-year.
- Alto Neuroscience, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-03-31 was 4.60M shares, a 60.61% decline year-over-year.
- Alto Neuroscience, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2023-03-31 was 11.67M shares.
- Alto Neuroscience, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 5.58M shares, a 7.39% increase from fiscal 2024.
- Alto Neuroscience, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 5.20M shares, a 70.13% decline from fiscal 2023.
- Alto Neuroscience, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 17.40M shares.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month |
|---|---|---|---|---|
| 2026-06-30 | 7.36M shares 10-Q · filed 2026-08-12 | |||
| 2026-03-31 | 7.25M shares 10-Q · filed 2026-05-13 | |||
| 2025-12-31 | 5.58M shares 10-K · filed 2026-03-16 | |||
| 2025-09-30 | 5.56M shares 10-Q · filed 2025-11-12 | |||
| 2025-06-30 | 5.82M shares 10-Q · filed 2026-08-12 | |||
| 2025-03-31 | 5.88M shares 10-Q · filed 2026-05-13 | |||
| 2024-12-31 | 5.20M shares 10-K · filed 2026-03-16 | |||
| 2024-09-30 | 5.04M shares 10-Q · filed 2025-11-12 | |||
| 2024-06-30 | 4.97M shares 10-Q · filed 2025-08-13 | |||
| 2024-03-31 | 4.60M shares 10-Q · filed 2025-05-14 | |||
| 2023-12-31 | 17.40M shares 10-K · filed 2025-03-20 | |||
| 2023-09-30 | 11.96M shares 10-Q · filed 2024-11-12 | |||
| 2023-06-30 | 12.33M shares 10-Q · filed 2024-08-13 | |||
| 2023-03-31 | 11.67M shares 10-Q · filed 2024-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |